Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Beni-Suef University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06405178CT.gov Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome | — | Completed | — | — | — |
NCT06576375CT.gov Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome | — | Recruiting | — | — | — |
NCT05601336CT.gov of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO | — | Unknown | — | — | — |
NCT04213677CT.gov Dapagliflozin Efficacy and Action in PCOS | — | Completed | — | — | — |
NCT02635386CT.gov EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Polycystic Ovary Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dapagliflozin (this asset) | Beni-Suef University | P3 | B · 63 |
| Semaglutide | Methodist Health System | P4 | BBB |
| Liraglutide | Peking University Third Hospital | P4 | BBB |
| Human Chorionic Gonadotropin | Eman Basuni Ebrahim Mowad | P4 | BBB |
| Follitropin Beta | Universitair Ziekenhuis Brussel | P4 | BBB |
| Drospirenone | Ege University | P4 | BBB |
| Ethinyl Estradiol | Ege University | P4 | BBB |
| Glucophage | Near East University, Turkey | P4 | BBB |
| Clomiphene Citrate | HITEC-Institute of Medical Sciences | P4 | BBB |
+41 more in the Polycystic Ovary Syndrome cohort
Other indications for Dapagliflozin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Type 2 Diabetes Mellitus | — | P4 | BBB · 78 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P4 | BBB · 77 |
| Arteriosclerosis Disorder | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dapagliflozin in Polycystic Ovary Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dapagliflozin-polycystic-ovary-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →